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1. Introduction
Alzheimer’s disease (AD) is a 
neurodegenerative disease char-
acterized by pathological fea-
tures of neurofibrillary tangles 
(tau pathology) and β-amyloid 
plaques in the cerebral cortex. In 
this case, pathology of β-amyloid 
plaques varies considerably, and 
neurofibrillary tangles are close-
ly correlated with symptoms of 
the disease and its progression 
[1]. Pathology of neurofibrillary 
tangles is associated with abnor-
mal aggregation of tau protein. 
Tau protein is associated with 
microtubules and stabilizes them 
after phosphorylation. Microtu-
bules are fulfilling the role of 
the cytoskeleton of the neuron. 
They are involved in the trans-
port of vital substances from the 
cell center towards the end of the 
axon and back. In Alzheimer’s 
disease, tau protein undergoes 
excess phosphorylation, due to 
which its threads begin to merge 
and form neurofibrillary tangles 
within nerve cells. This causes 
the destruction of microtubules 
and the collapse of the transport 
system within the neuron [2, 3]. 
Initially, this leads to disruption 
of the biochemical signals trans-
mission between cells, and then 
to their death [4].
It has been shown that GSK-3β 
(glycogen synthase kinase-3β) is a 
key factor in the phosphorylation 
of tau protein [5], its increased 
activity leading to pathologies of 
neurofibrillary tangles and, con-
sequently, to neurodegenerative 
changes in the brain [6, 7]. In this 
connection, the search for effec-
tive inhibitors of GSK-3β is a very 
important and urgent task, for 
their further use in the treatment 
of Alzheimer’s disease. In recent 
years, an increasing number of 
works devoted to this subject has 
appeared [8, 9].
As promising inhibitors of 
GSK-3β of 2-mercapto-1,3,4-oxa-
diazole derivatives (Fig. 1, a) 
have been proposed [10].
In this paper, we have pro-
posed N-amidoalkylated deriv-
atives of 2-amino-1,3,4-oxadiazole as potential inhibitors 
of GSK-3β (Fig. 1, b). The search for compounds leaders 
has been based on the results of the molecular docking [12]. 
The structures of the compounds for the prediction have 
been taken from our virtual library, their general synthesis 
methodology having been developed by us earlier [11, 13, 14].
a
b
Fig. 1. The structures of some 
inhibitors of GSK-3β:  
a– 2-mercapto-1,3,4-oxadiazole 




2. Materials and methods
We have carried out geom-
etry optimization of analyzed 
structures within PM3 semi-em-
pirical method, and GSK-3β mo-
lecular docking using software 
ArgusLab4.0.1 [15]. Previously, 
this software package was suc-
cessfully used to solve similar 
problems [16, 17].
The three-dimensional crys-
tal structure of co-crystallizer 
GSK-3β and 2-(benzo[d][1,3]dio- 
xol-5-yl)-5-((3-f luoro-4-metho- 
xybenzyl)thio)-1,3,4-oxadiazole 
(1) (PDB ID: 3F7Z) has been 
loaded in PDB format from the 
data bank of protein molecules 
(http://www.rcsb.org). The pro-
tein molecule is symmetrical 
and contains two active sites, 
and consequently, co-crystallizer 
contains two molecules of in-
hibitor (1). To be able to assess 
the root-mean-square deviation 
of atomic positions (RMSD) one 
molecule from (1) was previously 
removed. Crystalline inclusions 
PTR 216 and PTR 560 were also 
removed for ease of operation.
Before the molecular docking, 
the hydrogen atoms were added 
throughout the protein structure. 
The molecules of crystal water 
were not removed from the binding site since they were involved 
in the binding of the inhibitor by means of hydrogen bonds [10].
On the basis of remaining inhibitor molecule (1) (code in 
co-crystallizer 3000 340), we have created ligand group named 
Ligand_X-ray. A three-dimensional model of the binding site 
has been created on the basis of this group, its dimensions being 
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Abstract: Alzheimer's disease is a neurodegenerative dis-
ease characterized by pathological features of neurofibril-
lary tangles and β-amyloid plaques in the cerebral cortex. In 
Alzheimer's disease, tau protein undergoes excess phospho-
rylation, due to which its threads begin to merge and form 
neurofibrillary tangles within nerve cells. It has been shown 
that glycogen synthase kinase-3β is a key factor in the phos-
phorylation of tau protein, its increased activity leading to 
pathologies of neurofibrillary tangles and, consequently, to 
neurodegenerative changes in the brain. In this connection, 
the search for effective inhibitors of GSK-3β is a very impor-
tant and urgent task, for their further use in the treatment of 
Alzheimer's disease. 
Aim of research. The aim of this study is to search new in-
hibitors of GSK-3β among N-amidoalkylated derivatives of 
2-amino-1,3,4-oxadiazole by molecular docking methods. 
Materials and methods. We have carried out geometry op-
timization of analyzed structures within PM3 semi-empiri-
cal method, and GSK-3β molecular docking using software 
ArgusLab 4.0.1. The three-dimensional crystal structure of 
co-crystallizer GSK-3β and inhibitor has been loaded from 
the data bank of protein molecules (PDB ID: 3F7Z). 
Results. In this study it has been shown that the structures be-
ing studied mainly form stronger complexes with the enzyme 
compared to the known inhibitor. Based on the results of mo-
lecular docking, the compounds leaders N-(((5-(2-bromo-
phenyl)-1,3,4-oxadiazol-2-yl)amino)methyl)benzamide and 
2,4-dichloro-N-(2,2,2-trichloro-1-((5-(p-tolyl)-1,3,4-oxa- 
diazol-2-yl)amino)ethyl)benzamide have been chosen. The 
structures of the compounds leaders have been tested for 
compliance with Lipinski criteria. 
Conclusions. Proposed compounds leaders can be recom-
mended for further studies in the treatment of Alzheimer's 
disease. Despite the good results obtained in silico analysis, it 
is mandatory to perform biological tests in vitro and in vivo.
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calculated automatically and being along the X-axis – 19.967, 
Y-axis – 15.898 and the Z-axis – 17.203 Å. Docking has been 
done with a flexible ligand. A semi-empirical AScore function 
has been used to the scoring procedure, based on the XScore 
function [18]. The cell resolution has been set at 0.250 Å. The 
calculation type has been Dock; Docking Engine – ArgusLab. 
Visualization of the results has been carried out using program 
PyMOL [19].
3. Results
The active GSK-3β site is a large lipophilic pocket with small 
polar regions at opposite ends. In these areas, there are molecules 
of crystalline water, which take an active part in ligand-pro-
tein interactions. In carrying out molecular docking, we have 
used 2-(benzo[d][1,3]dioxol-5-yl)-5-((3-fluoro-4-methoxybenzyl)
thio)-1,3,4-oxadiazole (1) as a reference. According to X-ray 
diffraction analysis, the molecule of compound (1) interacts 
additionally with the active site of GSK-3β due to the formation 
of a complex system of intermolecular hydrogen bonds involving 
water molecules H2O 3121 and H2O 3120 and the Nitrogen atom 
of pyridine type of N(4) 1,3,4-oxadiazole rings. The Oxygen 
atom of the benzodioxole cycle and the amino acid valine 135 
also form the hydrogen bond, the bond length is 2.887 Å. The 
calculated energy of inhibitor binding (1) with the active site of 
the enzyme is -9.8475 kcal/mol, the calculation time – 5 seconds. 
The calculated position of the inhibitor in the active site of the en-
zyme is similar to the results obtained by X-ray analysis (Fig. 2), 
root-mean-square deviation of atomic positions (RMSD) is 1.4 Å. 
According to molecular docking data, the molecule of compound 
(1) interacts additionally with the active site of GSK-3β due to the 
formation of a complex system of intermolecular hydrogen bonds 
involving water molecules H2O 3121 and H2O 3120 and the Ni-
trogen atom of pyridine type of N(4) 1,3,4-oxadiazole rings. The 
Nitrogen atom of pyridine type of N(3) 1,3,4-oxadiazole rings and 
the amino acid asparagine 200 also form the hydrogen bond, the 





















Fig. 2. Position of compound (1) in active site of GSK-3β: 
a – according to X-ray analysis data [10]; b –according to 
molecular docking
According to the molecular docking, compounds (3), (4) 
have formed the most stable complexes with GSK-3β. N-(((5-(2-
Bromophenyl)-1,3,4-oxadiazol-2-yl)amino)methyl)benzamide 
(3) effectively binds to GSK-3β by the formation of two inter-
molecular hydrogen bonds (Fig. 3, a). Hydrogen bonds are 
formed by 1) The Nitrogen atom N(3) of the 1,3,4-oxadiazole 
cycle and -NH group of valine (135), bond length 2.988 Å; 2) The 
Hydrogen atom of the amine moiety and the Oxygen atom of 
valine (135), bond length 2.853 Å. The molecule of 2,4-dichloro-
N-(2,2,2-trichloro-1-((5-(p-tolyl)-1,3,4-oxadiazol-2-yl)amino)
ethyl)benzamide (4) is additionally fixed in the active center 
of InhA enzyme due to the complex system of intermolecular 
hydrogen bonds involving the molecules of crystalline water – 























Fig. 3. Position of N-amidoalkylated derivatives of 
2-amino-1,3,4-oxadiazolein GSK-3β active site according 
to the results of molecular docking:  
a – N-(((5-(2-bromophenyl)-1,3,4-oxadiazol-2-yl)amino)
methyl)benzamide (3); b – 2,4-dichloro-N-(2,2,2-tric 
hloro-1-((5-(p-tolyl)-1,3,4-oxadiazol-2-yl)amino)ethyl)
benzamide (4)
The compounds leaders have been tested for compliance 
with Lipinski criteria using Molinspiration web resource (http://
www.molinspiration.com/cgi-bin/properties). The compound 
(3) corresponds to them, while the compound (4) does not, since 
it has lipophilicity (log P) above 5.0.
4. Discussion
The above results showed that the novel N-amidoalkylat-
ed derivatives of 2-amino-1,3,4-oxadiazole has excellent 
potential as inhibitors of GSK-3β. They can be recommended 
for further studies in the treatment of Alzheimer’s disease. 
Their potential activity may be attributed with the signif-
icant interactions towards the inhibitor binding cavity of 
GSK-3β [20]. Also the molecules of the compounds leaders 
are additionally stabilized in the GSK-3β active center due to 
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the good results obtained in silico analysis, it is mandatory to 
perform biological tests in vitro and in vivo. It should be not-
ed that in addition to the compounds analyzed, similar series 
of 1,3,4-thiadiazole and 1,2,4-triazole derivatives should be 
studied, since their derivatives also have activity against Alz-
heimer’s disease [21, 22].
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